Eli Lilly’s Olumiant (baricitinib) Receives FDA’s Fast Track Designation for Systemic Lupus Erythematosus (SLE)

• The FDA’s designation is based on P-II study results assessing Baricitinib in patients with SLE,
  presented at European Congress of Rheumatology 2018
• Lilly is also evaluating baricitinib’s two doses in P-III SLE trials and for moderate-to -severe atopic dermatitis, with its expected results in H1’19
• Olumiant (baricitinib) 2mg is an inhibitor of janus kinase, further blocking its subtypes JAK1 and JAK2 and is approved in 50 countries for adults with rheumatoid arthritis

 Click here to read full press release/ article | Ref: Eli Lilly | Image:  iStock